Axillary nodal status is among the most important prognostic factors in breast cancer patients. SN biopsy with an intensive pathological assessment of selectively removed lymph nodes is currently a highly accurate, minimally invasive technique to assess nodal status.[@CR1],[@CR2] It reduces the morbidity of breast cancer surgery by avoiding unnecessary axillary lymph node dissection (ALND) in patients with negative sentinel nodes (SNs).[@CR3] The optimal treatment of patients with a positive SN is however less clear. The few SNs can be cost-effectively analyzed by multiple-level evaluation and immunohistochemistry (IHC) which increases the likelihood of detecting small metastases.[@CR4] The decision to proceed with an ALND in patients with macrometastatic SN involvement does not pose a major clinical dilemma. The need for routine ALND in patients with minimal SN involvement however continues to be debated since only a minority of these patients (10--15%) show non-SN involvement.[@CR5] Predicting the chance of involvement of the non-SN would facilitate the selection of patients with a potential therapeutic benefit of ALND.

Several features of the primary tumor and the involved SNs have been investigated as potential predictors for non-SN involvement. Primary tumor size, palpability, presence of peritumoral lymphovascular invasion, number of tumor-involved SNs, size of the SN metastases, and extracapsular extension (ECE) correlate with non-SN status.[@CR6]--[@CR10] However, none of these factors are sensitive and reproducible enough to reliably identify a subgroup of patients who might be spared ALND.

Several melanoma studies have reported that the microanatomic pattern of SN involvement and the penetrative depth (defined as the maximum distance of cancer cells from the inner margin of the SN capsule) predict non-SN involvement.[@CR11]--[@CR14] In breast cancer, this has been studied less extensively.[@CR15]We therefore set out to study the predictive value of microanatomic location and penetrative depth of SN metastatic deposits for non-SN metastases, accurately assessed by morphometry, in a large series of SN-positive breast cancer patients.

Patients And Methods {#Sec1}
====================

Patients {#Sec2}
--------

A retrospective database was analyzed, including patients with invasive breast cancer and a tumor positive axillary SN followed by ALND, treated at the University Medical Center Utrecht or the St Antonius Hospital in Nieuwegein from January 2000 to May 2007 (*n* = 357), including patients from our previous study.[@CR16] Exclusion criteria were multicentric tumors, neoadjuvant chemotherapy, and a total of fewer than six lymph nodes examined.

SN Biopsy Technique {#Sec3}
-------------------

The technical aspects used for the SN procedure are described in detail elsewhere.[@CR16] Briefly, before surgery, SN identification was performed by peritumoral injection of 120 MBq ^99m^Tc-Nanocolloid (Amersham Cygne, Eindhoven, The Netherlands) in a maximal volume of 0.5 mL. Dynamic and static scintigraphic images were subsequently obtained. On the same day, immediately preoperatively 0.5 mL Patent blue dye (Guerbet, Aulnay-sous-Bois, France) was injected intradermally and intra/peritumorally. The SN was identified after careful dissection of blue lymphatic channels and detection of radioactivity with a handheld gamma ray detection probe. Palpation of the open axilla was performed to detect enlarged non-SN metastases.

Histopathological Evaluation {#Sec4}
----------------------------

The SNs were processed according to the protocols described previously.[@CR16]--[@CR18] SNs were lamellated according to their size, fixed in neutral buffered formaldehyde, and completely embedded. Step sections 5 μm thick were cut at five levels with 250 μm intervals for staining with haematoxylin and eosin (H&E). In the absence of apparent metastases by H&E examination, immunohistochemistry was performed with CAM 5.2 (Beckton Dickinson, Franklin Lakes, New Jersey, USA) or CK AE1/3 (Dako, Glostrup, Denmark) at each level. All non-SNs were identified visually or by palpation, dissected, processed routinely, and examined at one level with H&E staining. All SNs and non-SNs were examined initially by multiple pathologists at the two institutions, reviewed histologically, and reclassified according to the current 6^th^ edition of the American Joint Committee on Cancer (AJCC) staging system by one observer (CHMvD). All cases were evaluated without knowledge of non-SN involvement.

Clinicopathological Features {#Sec5}
----------------------------

Clinicopathological features recorded included age, pT (TNM system of the AJCC), histological subtype (according to the WHO), histological grade (defined according to the Nottingham modified Bloom--Richardson score based on the percentage of tubule formation, nuclear pleomorphism and mitotic activity), mitotic activity index (MAI),[@CR19] steroid receptor and HER-2/*neu* status (not routinely determined before 2005).

SN and Non-SN Characteristics {#Sec6}
-----------------------------

SN characteristics included metastatic size according to the 6^th^ edition of the AJCC staging system \[isolated tumor cells (ITC) (≤0.2 mm), micrometastases (\>0.2 mm and ≤2 mm), macrometastases (\>2 mm)\], the number of SNs, ECE, maximal diameter of the largest metastases, microanatomic location of the metastatic deposit, and the penetrative depth. If multiple but distinct deposits were identified in the same SN, the largest metastasis was recorded. If single tumor cells, cluster of nests were continuous, or separated by a few cells distance, they were measured as one focus.[@CR20] If more than one SN was involved in an individual patient, the most extensive and/or deepest metastatic deposit was recorded. In case both axillary and internal mammary SNs were involved, the features were measured in the axillary SN.

The microanatomic location of metastatic deposits within each SN was classified as subcapsular, combined subcapsular and parenchymal, parenchymal or extensive. Extensive SN involvement, as defined in the study of Ruiter et al.,[@CR21] was a deposit \>5 mm in diameter (Fig. [1](#Fig1){ref-type="fig"}). The centripetal depth was, according to Starz et al.,[@CR11] defined as the maximal depth at which tumor cells have infiltrated the SN, as measured from the inner margin of the capsule (Fig. [2](#Fig2){ref-type="fig"}), further denoted *tumor penetrative depth* according to the proposal of Scolyer et al.[@CR12] Multifocality was defined as two or more separated metastatic deposits at some distance from each other. All measurements were calculated microscopically in the plane of the tissue sections using interactive video morphometry systems (Q-PRODIT, Leica, Cambridge, UK or Research Video Assistant, Baarn, The Netherlands). FIG. 1.Pattern of distribution of metastatic breast cancer deposits in SNs.FIG. 2.The tumor penetrative depth of metastases was defined as the maximal distance of breast cancer cells from the inner margin of the SN capsule (*arrow*) (H&E, original magnification × 10).

Non-SN characteristics included the total number of non-SNs, maximal tumor diameter, AJCC classification, and ECE. If more than one non-SN was involved, the largest diameter was recorded.

Statistical Analysis {#Sec7}
--------------------

Statistical analysis was performed using SPSS 13.0 for Windows. Patients were divided into groups with and without non-SN involvement. The Pearson chi-square test was used to determine the relationship between categorical variables (histological type and grade, steroid receptor and HER-2/*neu* status, number of SNs, AJCC classification, ECE) on the one hand and non-SN status on the other. Continuous data (age, diameter primary tumor, MAI, SN tumor diameter) were analyzed using the Mann--Whitney *U*-test. *P*-values \<0.05 were considered significant. All relevant variables that were associated with the presence of positive non-SNs were included in a multivariate logistic regression model. SN metastatic characteristics (diameter and penetrative depth) were further compared by receiver operating characteristic (ROC) analysis, calculating the area under curve (AUC) as a measure of discriminative value.

Results {#Sec8}
=======

The median age was 53 years (range 22--86 years) and the mean histological invasive tumor size was 2.4 cm (range 0.3--9.0 cm). Overall, 571 SNs were obtained (mean 1.6 SN per patient) of the 357 patients with a positive SN as well as 4939 non-SNs (mean 14 per patient). The metastatic deposits were subcapsular in 167 patients (47%), combined subcapsular and parenchymal in 40 patients (11%), parenchymal in 11 patients (3%), and extensive in 139 patients (39%) (Fig. [1](#Fig2){ref-type="fig"}). Of the 357 patients, 24 (7%) patients had ITC only in the SN, whereas 112 (31%) had micrometastases and 221 (62%) had macrometastases. Localisation of ITCs was subcapsular (96%) or parenchymal (4%). SN micrometastases were located subcapsularly (81%), parenchymally (5%) or had combined localisation (13%). The overall prevalence of non-SN involvement was 38% (136/357 patients). Other descriptive characteristics of the study population are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. TABLE 1.Clinicopathological characteristics of 357 invasive breast cancer patients with a positive SN and subsequent axillary lymph node dissectionFeatureNo.%Mean age (range)54 y (22--86)**Primary tumor**Mean tumor size (range)2.4 cm (0.3--9.0)  pT118752  pT215042  pT3195  pTx10Histological subtype  Invasive ductal cancer29884  Invasive lobular cancer3610  Others236Histological grade (B&R)  17421  216145  312234MAI, mean/2 mm^2^ (range)13 (0--102)Steroid receptor status  ER -- positive ‡32290  ER -- negative3410  ER -- unknown1  PR -- positive ‡28480  PR -- negative7020  PR -- unknown3HER-2/*neu* status  Positive2615  Negative15085  Unknown181‡ ≥10% immunoreactive neoplastic cells.TABLE 2.SN and non-SN characteristics of 357 invasive breast cancer patients with a positive SN and subsequent axillary lymph node dissectionFeatureNo.%**SN**Total number of SNs571Mean number of SNs1.6Total number of positive SNs419Mean diameter SN metastases4.7 mmAJCC classification of SN metastatic size  ITC247  Micrometastasis11231  Macrometastasis22162Extracapsular extension  No25772  Yes10028Microanatomic location  Subcapsular16747  Parenchymal113  Combined4011  Extensive13939Mean penetrative depth2.9 mm**Non-SNs**Total number of non-SNs4939Mean number of non-SNs (range)14 (5--38)Total number of positive non-SNs474Total number of negative non-SNs4465Size of non-SN metastases  ITC32  Micrometastases3324  Macrometastases10074

The following factors were significant predictors of non-SN metastases by univariate analysis: primary tumor size, number of involved SNs, ECE, AJCC classification, diameter, and penetrative depth of the SN metastatic deposit (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). None of the other classic variables (age, histological subtype and grade, steroid receptor and HER-2/*neu* status, MAI) of the primary tumor correlated significantly with non-SN involvement. TABLE 3.Comparison of categorical clinicopathological and SN characteristics in invasive breast cancer patients without and with non-SN metastases by Pearson chi-square testWithout non-SN metastasesWith non-SN metastases*P*value**Feature**No (%)No (%)Total221 (62)136 (38)Histological subtype0.914  Ductal183 (51)115 (32)  Lobular22 (6)14 (4)  Others16 (5)7 (2)Histological grade (B&R)0.798ER positive198 (56)124 (35)0.715  Negative22 (6)12 (3)PR positive179 (50)106 (30)0.589  Negative41 (12)29 (8)HER-2/*neu* positive16 (9)10 (6)0.670  Negative83 (47)67 (38)No. of SN0.246  1131 (37)89 (25)  \>190 (25)47 (13)No. of involved SN0.050  1198 (55)112 (31)  \>123 (6)24 (7)AJCC SN metastases\<0.001  ITC21 (6)3 (1)  Micrometastasis86 (24)26 (7)  Macrometastasis114 (32)107 (30)Extracapsular extension\<0.001  No175 (49)82 (23)  Yes46 (13)54 (15)Microanatomic location SN metastases\<0.001  Subcapsular126 (35)41 (11)  Combined23 (6)17 (5)  Parenchymal8 (2)3 (1)  Extensive64 (18)75 (21)Multifocality0.087  No176 (49)118 (33)  Yes45 (13)18 (5)TABLE 4.Comparison of continuous clinicopathological and SN characteristics in invasive breast cancer patients without and with non-SN metastases by Mann--Whitney U-testWithout non-SN metastasesWith non-SN metastases*P*value**Feature**Total no. (%)221 (62)136 (38)Age (years, mean)54530.249Primary tumor diameter, cm (mean)2.32.50.019MAI, 2mm^2^ (mean)13120.693SN tumor diameter, mm (mean)3.66.5\<0.001SN tumor penetrative depth, mm (mean)2.23.9\<0.001

The primary tumor features histological grade and diameter were associated with multiple SN tumor deposits (*P* = 0.03 and 0.05, respectively).

Frequency of non-SN metastases in patients with SN ITC (*N* = 24), micro- (*N* = 112) and macrometastases (*N* = 221) was 12.5%, 23%, and 48%, respectively (*P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}). Of those three patients with SN ITC and involved non-SNs, two had a non-SN micro- and one had a non-SN macrometastasis. One of these ITC was located in the parenchyma, the other two patients had a subcapsular location. Two of these three patients with SN ITC and non-SN involvement showed multiple small cell clusters and single cells in the SN. FIG. 3.Flow chart showing distribution of SN AJCC classification according to non-SN involvement.

The microanatomic localization of SN metastatic deposits correlated with non-SN involvement. Patients with subcapsular (*N* = 167), combined subcapsular and parenchymal (*N* = 40), parenchymal (*N* = 11) and extensive (*N* = 139) tumor deposits showed non-SN involvement in 25%, 42%, 27%, and 54% of cases, respectively (Table [3](#Tab3){ref-type="table"}). Morphometrically assessed penetrative depth of SN metastases was also associated with non-SN involvement. Frequency of non-SN metastases in patients with a SN tumor penetrative depth \<0.155 mm (*N* = 29), 0.155--2.7 mm (*N *= 181) and \>2.7 mm (*N* = 147) was 10%, 28%, and 56%, respectively (*P* \< 0.001, Table [5](#Tab5){ref-type="table"}). In ROC analysis, diameter (AUC = 0.686) and the penetrative depth (AUC = 0.680) of the SN tumor deposit had comparable discriminative value (Fig. [4](#Fig4){ref-type="fig"}). TABLE 5.Predictive value of penetrative depth of SN metastases for non-SN involvement in patients with invasive breast cancerSN penetrative depth (mm)*N*No. of patients with non-SN involvement (%)\<0.155293 (10)0.155--2.718151 (28)\>2.714782 (56)FIG. 4.ROC curves showing the sensitivity and specificity of SN tumor diameter and penetrative depth as predictors of non-SN involvement. The larger the area below the curve, the more accurate the prediction of non-SN involvement (*P* \< 0.001).

In multivariate analysis, SN tumor diameter (*P* = 0.032) and SN tumor penetrative depth (\<0.155 mm versus 0.155--2.7 mm versus \>2.7 mm) (*P* = 0.015) were significant in predicting non-SN involvement. Cutoff values were interactively statistically as those best discriminating between low and high risk of non-SN metastases. Risk stratification by combining these features identified a low-risk group, an intermediate-risk group, and a high risk group for non-SN metastases with frequency of non-SN metastases in 11%, 29%, and 56% of patients, respectively (Table [6](#Tab6){ref-type="table"}). Frequencies of non-SN involvement in patients with SN micrometastases and a subcapsular (*N* = 91), combined subcapsular and parenchymal (*N* = 15), and parenchymal location (*N* = 6) were 21%, 40%, and 17%, respectively**.**Frequencies of non-SN involvement in patients with SN macrometastases and a subcapsular (*N* = 54), combined subcapsular and parenchymal (*N* = 25), parenchymal (*N* = 4) and extensive location (*N* = 138) were 39%, 44%, 25%, and 54%, respectively. TABLE 6.Predictive value of a combination of AJCC classification of SN metastases and penetrative depth of SN metastases for non-SN involvement in patients with invasive breast cancer*N*No. of patients with non-SN involvement (%)ITC/SN penetrative depth \< 2.7 mm or Micrometastases/penetrative depth \< 0.155 mm384 (11)Micro- or macrometastases/penetrative depth 0.155--2.7 mm17250 (29)Micro- or macrometastases/penetrative depth \>2.7 mm14782 (56)

Discussion {#Sec9}
==========

The lymphatic spread of breast cancer cells has been shown to follow an orderly progression via the SN to non-SNs, which implies that the risk of spread of tumor from the SN to the non-SN may depend on the extent of SN involvement. While many studies have focused on the maximal diameter of the metastatic tumor deposit[@CR22]^,^[@CR23] we investigated the microanatomic location and the penetrative depth of the metastatic deposits as a putative predictor of non-SN involvement. This was based on the concept that within the SN, tumor cells also follow an orderly route, arriving in the subcapsular sinuses through an afferent lymph vessel. Later, there is subcapsular outgrowth of malignant cells in the marginal sinuses and into the cortical parenchyma. Finally, these cells extend to the deeper zones of the lymph node parenchyma, frequently following the medullary sinuses to efferent lymph vessels.[@CR24] Consistent with this concept we found that the microanatomic location, the size, and the penetrative depth of SN tumor deposits were correlated significantly with non-SN involvement. This finding is consistent with recent melanoma studies. Startz et al.[@CR11] proposed a micromorphometric classification, based on the depth of the metastasis from the capsule and the number of 1-mm slices containing melanoma. This classification was a highly significant predictor for distant metastases and overall survival. Dewar et al.[@CR13] also recorded that the microanatomic location of melanoma SN metastases predicts non-SN involvement, and proposed that it would be possible to safely avoid a lymph node dissection in patients with subcapsular deposits only. Indeed, subcapsular location and small tumor penetrative depth correlated with less non-SN involvement in our breast cancer study, although no subgroup of patients could be selected without non-SN involvement.

The measurement of the SN tumor penetrative depth was difficult in many cases, especially in case of extensive tumor deposits. In these cases the tumor deposits frequently extended beyond the center of the lymph node, making it difficult to determine which edge of the SN capsule should be used to measure the tumor penetrative depth. Similar difficulties were encountered when the SN had a lobulated outline. Further studies which more rigorously define the tumor penetrative depth may strengthen its predictive power and reproducibility.

In conclusion, patients with breast carcinoma and SN involvement can be stratified into subgroups at significantly different risk for non-SN involvement, according to microanatomic localization of the SN metastatic deposits and penetrative depth into the SN. However, based on these features no subgroup of patients could be selected without non-SN involvement.
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